UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

(PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma)) Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers.

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder ("Fortress"; Nasdaq: FBIO), have entered into a royalty agreement ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhanc ...

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for the stock to gain brownie points.

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.